Compare AbbVie Inc (ABBV) vs United Microelectronics Corp (UMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs United Microelectronics Corp — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while United Microelectronics Corp trades at $24.7 (market cap $60.80B). The key difference: AbbVie Inc is far larger — about 7.4× United Microelectronics Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | UMC | |
|---|---|---|
Market Cap | $449.91B | $60.80B |
Sector | Health | Technology |
52-Week High | $261.07 | $28.02 |
52-Week Low | $184.85 | $6.58 |
Enterprise Value | $513.38B | $58.38B |
Dividend Yield | 2.72% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
UMC trades at $23.83, down 2.89% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $237.55 billion in 2025, though net income margin compressed to 16.99%. The company maintains strong cash flow from operations and announced a $0.41 dividend for H2-26, reflecting financial stability amid competitive semiconductor market dynamics.
Outlook remains supported by specialty chip demand and 14nm eHV platform innovation, but valuation multiples like P/E of 41.94 suggest premium pricing. Risks include margin pressure and industry cyclicality, while analyst consensus leans hold with 53.33% neutral ratings, indicating cautious optimism for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
